Biotechnology
US oncology specialist Crescent Biopharma has announced an exclusive partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical. 4 December 2025
Biotechnology
Swiss late-stage biotech Pharvaris saw its shares rise 17% to $28.24 today, as it announced RAPIDe-3 pivotal data confirming the potential of deucrictibant’s differentiated profile for the on-demand treatment (ODT) of hereditary angioedema (HAE) attacks. 3 December 2025
Biotechnology
US healthcare giant Johnson & Johnson has announced that the European Commission has approved a marketing authorization for Imaavy (nipocalimab), a fully human FcRn-blocking monoclonal antibody, as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG). 2 December 2025
Pharmaceutical
The UK government has sealed a deal to give the USA zero tariffs on pharmaceutical products imported into the country, in return for the National Health Service (NHS) spending more on medicines. 1 December 2025
Biotechnology
Zhongmou Therapeutics, a Chinese genomic medicine company focused on restoring vision through gene and optogenetic therapies, has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to begin a multinational, randomized, single-masked, sham-controlled clinical trial (PRISM) of ZM-02. 28 November 2025
Most Read
Features
Company Spotlight
A clinical-stage biopharmaceutical company developing oral therapies for bradykinin-mediated angioedema, led by deucrictibant for hereditary angioedema (HAE) as both on-demand and prophylactic treatment options.
Recent news
Pharmaceutical
Last week the US Center for Biologics Evaluation and Research (CBER) released its plans for evaluating vaccines prompted by deaths associated with COVID-19 jabs. US drug developer Belite Bio announced positive Phase III trial results for its Stargardt disease candidate tinlarebant. Pharvaris released encouraging new Phase III data for its hereditary angioedema (HAE) investigational drug deucrictibant. Also of note, the UK and US governments sealed an agreement whereby British medicines exports to the USA will carry zero tariffs while the UK will pay higher prices for medicines. 7 December 2025
Biotechnology
US biopharma Vertex Pharmaceuticals today announced data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in people ages five years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). 6 December 2025
Pharmaceutical
Praxis Precision Medicines surged 35% with shares reaching a value of $260, their highest value since the beginning of 2022. Current market cap is ~$6.5 billion, after EMBOLD study success and strong pipeline progress, reaching its highest valuation since early 2022. 6 December 2025
Biotechnology
German cancer specialist Immatics announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering, with the news sending the firm’s shares up 13.5% to $10.26. 5 December 2025
Biotechnology
Swiss immunotherapy firm Neurimmune announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with UK pharma major AstraZeneca’s Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009. 5 December 2025
Refine Search
In Brief
Pharmaceutical
22 November 2025 US pharma giant Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1 trillion market valuation, a sharp turnaround from this summer when its stock was hit by disappointing results for a new obesity pill orforglipron, according to the Financial Times.
Generics
18 November 2025 India’s Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for diroximel fumarate delayed-release capsules, 231mg (Biogen’s Vumerity delayed-release capsules, 231mg).
Conferences
17 October 2025 21 October 2025 Berlin, Germany, Messe Berlin
9 December 2025 11 December 2025 London, UK, Savoy Place
9 December 2025 10 December 2025 Barcelona, Spain, InterContinental Barcelona
3 December 2025 5 December 2025 Sydney, Australia, University of Sydney
25 November 2025 27 November 2025 Greater Noida, India, India Expo Centre
24 November 2025 25 November 2025 London, UK, Kensington Conference & Events Centre
More Events
Insights
Pharmaceutical
Pulmonary arterial hypertension (PAH) is a rare, progressive, and often fatal cardiopulmonary condition characterized by pulmonary vascular remodeling and progressive narrowing, leading to increased pulmonary vascular resistance and pulmonary arterial pressure. 1 December 2025
Pharmaceutical
International understanding of China’s arrival as a leading player on the world stage as an innovator of new medicines is now ubiquitous. 29 November 2025
Biotechnology
Chinese biotech companies are pivoting from "fast-follow" to "smart" first-in-class (FIC) innovation, a shift that is reshaping global licensing deals and driving multinational corporations (MNCs) to integrate more deeply with China’s R&D ecosystem. 26 November 2025
Pharmaceutical
An Expert View from Alistair Henry, executive vice president, chief scientific officer and head of patient solutions, UCB. 25 November 2025
Pharmaceutical
In the last week, the European Medicines Agency, Italy’s Agenzia Italiana del Farmaco and China’s National Medical Products Administration have all moved on new therapies, pricing and traditional medicine standards, keeping pipelines and formularies in steady flux. 25 November 2025
Generics
The Russian drugmaker Akselpharm has successfully defended its patent for osimertinib the active ingredient of UK pharma major AstraZeneca’s in the Russian court, reports The Pharma Letter’s local correspondent. 24 November 2025
Pharmaceutical
New FIBRONEER results were presented by Boehringer Ingelheim at this year’s European Respiratory Society (ERS) International Congress that bring a new dimension to the nerandomilast Phase III data story in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). 21 November 2025
One to Watch Companies
One to watch
A privately-held French biotech advancing a clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases.
One to watch
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases.
One to watch
Privately-held GAIA is focused on the development of evidence-based, safe and accessible AI-powered digital therapeutics (DTx) that help patients restore and maintain their mental and physical health.
One to watch
Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.
Boardroom
Pharmaceutical
Danish allergy immunotherapy specialist ALK-Abello has appointed Edward Jordan as new executive vice president (EVP) and head of commercial operations in North America, effective January 5, 2026. 3 December 2025
Biotechnology
Trimtech Therapeutics, a UK biotech developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as chairwoman of its board of directors. 2 December 2025
Biotechnology
Privately-held German biotech Tacalyx has appointed Jean Engela as chief executive (CEO). 2 December 2025
Pharmaceutical
UK-based NRG Therapeutics has announced the expansion of its team with the appointment of Paul Thompson as chief development officer (CDO). 1 December 2025
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze